Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Icrucumab |
| Trade Name | |
| Synonyms | IMC-18F1|IMC18F1 |
| Drug Descriptions |
Icrucumab (IMC-18F1) is a monoclonal antibody that binds FLT1 (VEGFR1) to prevent ligand-based activation, which may result in decreased angiogenesis and tumor growth (PMID: 17085673, PMID: 28220020). |
| DrugClasses | |
| CAS Registry Number | 1024603-92-6 |
| NCIT ID | C79808 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Docetaxel + Icrucumab | Docetaxel Icrucumab | 0 | 0 |
| Icrucumab | Icrucumab | 0 | 0 |